An experimental drug from Cytokinetics has shown promising Phase 3 results in improving heart function during exercise for patients with obstructive hypertrophic cardiomyopathy (oHCM), a rare cardiovascular disease. The drug, aficamten, demonstrated a significant increase in peak oxygen uptake compared to a placebo and had a consistent treatment effect across patient subgroups. The drug works by stabilizing the heart muscle protein myosin to prevent excessive contractions. In comparison to a similar drug on the market, aficamten showed a potential advantage in terms of safety profile and could support a less restrictive Risk Evaluation and Mitigation Strategy program. The full results of the study will be presented at an upcoming medical conference.
Source link
Cytokinetics Heart Drug’s Trial Data Look Competitive With BMS Med Camzyos
